Close Menu

NEW YORK ­– Quest Diagnostics and the US Food and Drug Administration announced on Saturday that the company received Emergency Use Authorization from the FDA to for the use of Quest's SARS-CoV-2 RNA test for pool sampling to detect the coronavirus.

The agency reissued an EUA to the Secaucus, New Jersey-based company for the test, which is the first to receive the designation for pooled sampling for COVID-19 testing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Wall Street Journal, the Food and Drug Administration may soon issue an Emergency Use Authorization for convalescent plasma to treat COVID-19 patients.

Minnesota police have used genetic genealogy to make an arrest in a 1986 cold case, reports NBC News.

Researchers have used CRISPR-Cas9 to efficiently target a cephalopod pigmentation gene, as they report in Current Biology.

In Science this week: chromatin accessibility of microglia during fetal development, and more.